Brain arteriovenous malformation (bAVM) surgery is a major neurosurgical intervention performed to eliminate an abnormal vascular connection between cerebral arteries and veins. In a healthy brain, high-pressure blood from arteries passes through microscopic capillaries to deliver oxygen before entering low-pressure veins. An AVM lacks these capillaries, creating a central vascular tangle called a nidus where high-pressure blood flows directly into fragile veins, causing them to stretch, weaken, and potentially rupture.

The primary goal of microsurgical resection is complete obliteration of the nidus while preserving surrounding healthy brain tissue and critical blood vessels. By permanently isolating and removing the malformation, neurosurgeons eliminate the future risk of intracranial hemorrhage (bleeding inside the brain), reduce or control seizure activity, and prevent progressive neurological deficits caused by vascular steal syndrome (hypoperfusion of adjacent brain tissue due to blood diversion).

AVM brain surgery is performed under general anesthesia in a dedicated neurosurgical suite equipped with intraoperative angiography, continuous neurophysiological monitoring (SSEP/MEP), and neuronavigation guidance. The patient's head is stabilized in a rigid three-pin fixation device. A targeted skin incision is made, and a craniotomy bone flap is fashioned directly overlying the malformation. The dura mater is carefully incised and reflected.

Using a high-powered operating microscope, the neurosurgeon identifies the major feeding arteries supplying the nidus. These feeding vessels are micro-dissected and occluded using microvascular clips or bipolar electrocautery, taking care to preserve en-passage arteries supplying healthy brain tissue. The surgeon meticulously circumscribes the border between the AVM nidus and surrounding brain parenchyma, maintaining a precise dissection plane.

Throughout dissection, the primary draining vein is carefully protected to maintain outflow and prevent acute intranidal pressure spikes that could cause premature intraoperative rupture. Once all arterial feeding branches are detached and the nidus is fully mobilized, the primary draining vein is double-clipped and divided. The intact nidus is removed in its entirety.

The resection cavity undergoes strict hemostasis testing, often accompanied by lowering systemic blood pressure or performing intraoperative digital subtraction angiography or indocyanine green (ICG) videoangiography to verify total eradication and patent normal cerebral blood flow. The dura mater is closed in a watertight fashion, the bone flap is reattached with titanium microplates and screws, and the scalp is closed in layers.

Definitive microsurgical resection of a brain AVM offers significant long-term clinical advantages when performed on appropriately selected candidates:

• Immediate and Permanent Hemorrhage Elimination: Complete surgical removal provides an immediate, verified cure, eliminating the lifelong baseline 2% to 4% annual rupture risk (Spetzler & Martin, 1986; Lawton et al., 2015).
• Superior Curative Rate for Low-Grade Lesions: Microsurgery yields complete obliteration rates exceeding 95% to 98% for Spetzler-Martin Grade I and II AVMs upon immediate postoperative angiography.
• Improved Seizure Control: Resection of the nidus along with the adjacent gliotic, hemosiderin-stained brain tissue achieves complete seizure freedom or significant seizure reduction in over 70% to 80% of patients presenting with AVM-associated epilepsy (Englot et al., 2012).
• Reversal of Vascular Steal Ischemia: Removing the low-resistance vascular shunt restores normal perfusion pressure to surrounding functional brain tissue, stabilizing or improving chronic neurological deficits.
• Single-Stage Resolution: Unlike stereotactic radiosurgery, which requires a latency period of 2 to 3 years to induce vessel closure, surgery achieves instant vascular eradication without a prolonged latency window of residual hemorrhage risk.

Recovery from AVM brain surgery proceeds across distinct physiological phases, extending from intensive hospital monitoring to long-term functional reintegration:

• Phase 1: Hospitalization & Neuro-ICU (Days 1–5): Patients spend the first 24 to 48 hours in an intensive care setting with strict intravenous blood pressure management to prevent normal perfusion pressure breakthrough (brain swelling or hemorrhage caused by sudden re-routing of blood flow into previously underperfused vessels). Drains are removed, and mobility is gradually re-introduced.
• Phase 2: Subacute Home Recovery (Weeks 1–6): Pain is managed with oral analgesics. Fatigue is common as the brain heals. Patients must refrain from driving, heavy lifting (over 5 kilograms), strenuous exercise, and bending forward. Suture or staple removal typically occurs between 10 and 14 days post-op.
• Phase 3: Outpatient Rehabilitation (Months 1–3): Patients experiencing focal motor, language, or cognitive deficits undergo structured physical, occupational, or speech rehabilitation. Follow-up diagnostic catheter angiography is performed between 6 and 12 weeks to confirm zero residual AVM flow.
• Phase 4: Full Reintegration (Months 3–6+): Clearance for work, light cardiovascular exercise, and routine daily activities is granted sequentially based on clinical evaluation and imaging validation. Neurological recovery continues for up to 12 to 18 months due to neuroplasticity.

Microsurgical resection addresses specific cerebral vascular lesions and associated clinical complications, including:

• Ruptured Brain Arteriovenous Malformations: AVMs that have bled, presenting as acute parenchymal, intraventricular, or subarachnoid hemorrhage.
• Unruptured Brain Arteriovenous Malformations: Intact high-risk vascular tangles identified following seizures, chronic headaches, or incidental neuroimaging.
• AVM-Related Epilepsy: Recurrent focal or generalized seizures triggered by cortical irritation from adjacent vascular malformations or hemosiderin deposition.
• Progressive Focal Neurological Deficits: Motor weakness, sensory loss, or visual changes caused by regional ischemia (vascular steal) or mass effect from dilated vascular structures.
• Pediatric Cerebrovascular Malformations: Congenital high-flow vascular malformations in children and young adults requiring definitive anatomical cure.

Preoperative preparation for brain AVM surgery requires comprehensive anatomical mapping, medical stabilization, and multidisciplinary planning. Diagnostic testing includes high-resolution six-panel digital subtraction angiography (DSA) to identify feeder vessel origins, deep versus superficial venous drainage, and intranidal or flow-related aneurysms. Functional MRI (fMRI) or magnetoencephalography (MEG) may be ordered to map essential motor and language pathways relative to the nidus.

Patients undergo routine pre-anesthesia evaluations, including complete blood counts, coagulation profiles, metabolic panels, chest radiography, and electrocardiography. Anticoagulant and antiplatelet medications (e.g., aspirin, warfarin, clopidogrel, direct oral anticoagulants) must be discontinued under medical supervision 3 to 7 days prior to surgery to minimize intraoperative bleeding risks.

If preoperative embolization is recommended to decrease surgical complexity, it is scheduled 1 to 3 days prior to the craniotomy. Patients are started on prophylactic antiseizure medications (such as levetiracetam) prior to or during surgery. NPO (nothing by mouth) guidelines strictly mandate no solid foods for 8 hours and no clear liquids for 2 hours before induction of anesthesia.

Surgical risks for AVM resection depend strongly on the Spetzler-Martin grade, lesion location, patient age, and rupture status. Common, mild side effects include surgical incisional pain, localized scalp numbness, temporary fatigue, mild headaches, and soft tissue swelling around the eyes or surgical site.

Uncommon complications (occurring in 2% to 8% of low-to-medium grade resections) include postoperative focal neurological deficits such as mild transient limb weakness, transient speech difficulties (aphasia), minor visual field cuts, localized wound infection, cerebrospinal fluid (CSF) leakage, or postoperative seizures.

Rare but serious complications (occurring in 1% to 3% of low-grade cases and up to 15-30% in high-grade complex cases) include major intracranial hemorrhage from incomplete resection or normal perfusion pressure breakthrough, acute cerebral ischemic stroke from accidental occlusion of vessel-of-passage, severe brain edema, deep vein thrombosis or pulmonary embolism, status epilepticus, coma, or death. Long-term neurosurgical cohort studies confirm that operative mortality for low-grade (Spetzler-Martin I-II) AVMs is under 1%, whereas high-grade (Grade IV-V) lesions carry significantly higher morbidity rates, leading guidelines to recommend multimodal or conservative non-surgical management for most Grade IV-V malformations.

The clinical care pathway for brain AVM surgery spans diagnostic evaluation, surgical intervention, intensive care, and longitudinal neurosurgical follow-up:

• Diagnostic Workup: Preoperative mapping using high-resolution magnetic resonance imaging (MRI), computed tomography angiography (CTA), and six-panel catheter digital subtraction angiography (DSA) to characterize arterial feeders, nidus size, venous drainage pathways, and proximity to eloquent cortex (areas of the brain controlling speech, movement, or vision).
• Preoperative Embolization (Optional): In select complex malformations, an interventional neuroradiologist may perform targeted endovascular embolization (injecting liquid embolic agents into feeder vessels) 24 to 72 hours before open surgery to reduce blood flow and simplify surgical resection.
• Microsurgical Resection: Under general anesthesia, a neurosurgeon performs a craniotomy (removal of a section of skull bone), opens the protective dura mater membrane, uses a surgical microscope to clip feeder arteries, circumscribes the nidus, divides the primary draining vein last, and extracts the malformation.
• Immediate Postoperative Care: Transfer to a dedicated Neuroscience Intensive Care Unit (neuro-ICU) for 24 to 48 hours of continuous arterial blood pressure regulation, neuro-checks, and cerebral edema monitoring.
• Inpatient Recovery & Therapy: Transition to the neurosurgical ward for 3 to 5 days, incorporating physical, occupational, or speech therapy assessments.
• Angiographic Verification & Follow-up: A catheter DSA is performed either intraoperatively or at 6 to 12 weeks post-surgery to confirm complete AVM eradication, followed by clinical reviews at 3, 6, and 12 months.